DE60120138T8 - AMID COMPOUNDS AND ITS USE - Google Patents

AMID COMPOUNDS AND ITS USE Download PDF

Info

Publication number
DE60120138T8
DE60120138T8 DE60120138T DE60120138T DE60120138T8 DE 60120138 T8 DE60120138 T8 DE 60120138T8 DE 60120138 T DE60120138 T DE 60120138T DE 60120138 T DE60120138 T DE 60120138T DE 60120138 T8 DE60120138 T8 DE 60120138T8
Authority
DE
Germany
Prior art keywords
compound
drug
shows
hydrogen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE60120138T
Other languages
German (de)
Other versions
DE60120138T2 (en
DE60120138D1 (en
Inventor
Shinichi Takanashi
Yoichiro Naito
Hiroshi Tanaka
Masayoshi Uehata
Koshiro Katayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of DE60120138D1 publication Critical patent/DE60120138D1/en
Publication of DE60120138T2 publication Critical patent/DE60120138T2/en
Publication of DE60120138T8 publication Critical patent/DE60120138T8/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)

Abstract

The present invention relates to an amide compound of the formula <CHEM> wherein R<1> is a hydrogen and the like, R<2> is a hydrogen and the like, X is SO2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.
DE60120138T 2000-03-16 2001-03-16 AMID COMPOUNDS AND ITS USE Active DE60120138T8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000074764 2000-03-16
JP2000074764 2000-03-16
PCT/JP2001/002132 WO2001068607A1 (en) 2000-03-16 2001-03-16 Amide compounds and use thereof

Publications (3)

Publication Number Publication Date
DE60120138D1 DE60120138D1 (en) 2006-07-06
DE60120138T2 DE60120138T2 (en) 2007-03-29
DE60120138T8 true DE60120138T8 (en) 2007-10-11

Family

ID=18592757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120138T Active DE60120138T8 (en) 2000-03-16 2001-03-16 AMID COMPOUNDS AND ITS USE

Country Status (16)

Country Link
US (1) US6933305B2 (en)
EP (1) EP1270570B1 (en)
JP (1) JP4776136B2 (en)
KR (2) KR100818061B1 (en)
CN (1) CN1198804C (en)
AT (1) ATE327993T1 (en)
AU (1) AU2001241183A1 (en)
CA (1) CA2403321C (en)
CY (1) CY1105575T1 (en)
DE (1) DE60120138T8 (en)
DK (1) DK1270570T3 (en)
ES (1) ES2266171T3 (en)
HK (1) HK1049837B (en)
PT (1) PT1270570E (en)
SI (1) SI1270570T1 (en)
WO (1) WO2001068607A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100865262B1 (en) * 2001-04-11 2008-10-24 센주 세이야꾸 가부시키가이샤 Visual function disorder improving agents
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
EP1500643A4 (en) * 2002-04-03 2007-03-28 Dainippon Sumitomo Pharma Co Benzamide derivatives
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
ATE525111T1 (en) * 2003-04-18 2011-10-15 Senju Pharma Co 2-CHLORO-6,7-DIMETHOXY-N-5 Ä5-(1)H-INDAZOLYLUQUINAZOLINE-4-AMINE, N-(1-BENZYL-4-PIPERIDINYL)-1H-INDAZOLE-5-AMINE DIHYDROCHLORIDE, 4-Ä2 -(2,3,4,5,6-
CN100390173C (en) * 2003-06-06 2008-05-28 旭化成制药株式会社 Tricyclic compound
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
TWI346112B (en) * 2004-02-25 2011-08-01 Nissan Chemical Ind Ltd Benzopyran compound
KR100994173B1 (en) * 2004-12-27 2010-11-15 알콘, 인코퍼레이티드 Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
CR9465A (en) * 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
JP4972551B2 (en) 2005-06-21 2012-07-11 興和株式会社 Preventive or therapeutic agent for glaucoma
ES2416334T3 (en) 2005-07-12 2013-07-31 Kowa Company. Ltd. Agent for the prevention or treatment of glaucoma
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7655662B2 (en) 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
EP1891958A1 (en) * 2006-08-03 2008-02-27 Universite Pierre Et Marie Curie (Paris Vi) Rho/Rock/PI3/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites.
US20090036465A1 (en) * 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2009079011A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
WO2009079009A1 (en) * 2007-12-19 2009-06-25 Yangbo Feng Anilides and analogs as rho kinase inhibitors
US20110150833A1 (en) * 2007-12-21 2011-06-23 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
EP2628482A1 (en) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho kinase inhiitors for use in the treatment of neuroblastoma
WO2018052967A1 (en) * 2016-09-13 2018-03-22 Arbutus Biopharma, Inc. Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE9900050A (en) * 1996-08-12 1999-08-16 Yoshitomi Pharmaceutical Industries, Ltd. A pharmaceutical agent containing an Rho kinase inhibitor
JPH11130751A (en) * 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd Labeled compound of amide compound and acid adduct salt thereof
JP2000063274A (en) * 1998-08-20 2000-02-29 Yoshitomi Pharmaceut Ind Ltd Inhalant for asthma control

Also Published As

Publication number Publication date
PT1270570E (en) 2006-10-31
KR100818061B1 (en) 2008-04-01
DE60120138T2 (en) 2007-03-29
KR20070087087A (en) 2007-08-27
CN1198804C (en) 2005-04-27
DK1270570T3 (en) 2006-10-02
KR20020081455A (en) 2002-10-26
CA2403321C (en) 2009-07-14
US6933305B2 (en) 2005-08-23
ES2266171T3 (en) 2007-03-01
AU2001241183A1 (en) 2001-09-24
DE60120138D1 (en) 2006-07-06
KR100818060B1 (en) 2008-03-31
CY1105575T1 (en) 2010-07-28
EP1270570A1 (en) 2003-01-02
CA2403321A1 (en) 2001-09-20
HK1049837A1 (en) 2003-05-30
US20030158413A1 (en) 2003-08-21
ATE327993T1 (en) 2006-06-15
SI1270570T1 (en) 2006-10-31
HK1049837B (en) 2007-01-19
EP1270570A4 (en) 2004-02-18
WO2001068607A1 (en) 2001-09-20
JP4776136B2 (en) 2011-09-21
EP1270570B1 (en) 2006-05-31
CN1418194A (en) 2003-05-14

Similar Documents

Publication Publication Date Title
DE60120138T8 (en) AMID COMPOUNDS AND ITS USE
IS2293B (en) Aryl fused azapolycyclic compounds
ATE361287T1 (en) NEW INDOL-2-ON DERIVATIVES
SE0104332D0 (en) Therapeutic agents
NO20053645L (en) (4R) - and (4S) -diastereoisomers of (2S) -2- [2-oxy-4-propylpyrrolidinyl] butanamide and pharmaceutical composition containing these
SE0104334D0 (en) Therapeutic agents
MXPA04004464A (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease.
WO2002080846A3 (en) Epothilone derivatives and methods for making and using the same
TNSN04165A1 (en) Substituted hydroxyethylamines
ATE294185T1 (en) NEW PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR SALTS THEREOF AND INTERMEDIARIES FOR THE PRODUCTION OF THE DERIVATIVES
DK1065204T3 (en) Bicyclic carbonyl indole compounds as anti-inflammatory / analgesic agents and as COX-2 inhibitors
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
FI970317A (en) Compounds useful as antiproliferative agents and Garft inhibitors
SE0400043D0 (en) New compounds
JO2321B1 (en) 4-phenyl-pyridine derivatives
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
PT992509E (en) NEW MACROLIDED DERIVATIVES
NO307464B1 (en) Galantamine derivatives, pharmaceutical compositions containing the same and their use in the manufacture of medicaments
ATE240098T1 (en) SUBSTANCES FOR INHIBITING THE FORMATION OF THE PTERYGIUM AND ITS POSTOPERATIVE RECURRENCE
ATE398614T1 (en) TRIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE
SE0104333D0 (en) Therapeutic agents
HUP0302820A2 (en) Indole derivatives useful for the treatment of cns disorders and pharmaceutical compositions containing them
ATE252546T1 (en) 3-(3-HYDROXYPHENYL)-3-AMINO-PROPIONAMIDE DERIVATIVES
DK0952157T3 (en) 9a, 11b-dehydro derivatives of 9-oxime-3-keto-6-O-methylerythromycin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8381 Inventor (new situation)

Inventor name: TAKANASHI, SHINICHI, TOKYO, JP

Inventor name: NAITO, YOICHIRO, TOKYO, JP

Inventor name: TANAKA, HIROSHI, TOKYO, JP

Inventor name: UEHATA, MASAYOSHI, TOKYO, JP

Inventor name: KATAYAMA, KOSHIRO, TOKYO, JP